Tesofensine is a serotonin-noradrenaline-dopamine reuptake inhibitor originally developed for Parkinson's and Alzheimer's disease that produces approximately 10% body weight loss over 24 weeks — significantly more than any approved oral weight loss drug at the time of its trials.
This peptide profile is for research and educational purposes only. Not intended for human use or self-administration.
Overview
Tesofensine (NS2330) is a triple monoamine reuptake inhibitor developed by Neurosearch that simultaneously blocks the reuptake of serotonin, noradrenaline, and dopamine. It was originally investigated for Parkinson's and Alzheimer's disease, where dopamine restoration is beneficial — but trials were discontinued after Phase 2 when the neurological indications were not met at safe doses. However, the trials revealed unexpectedly significant weight loss as a side effect, leading to repurposing for obesity treatment. Phase 2b obesity trials showed dose-dependent weight loss of 6.5–10.6% body weight over 24 weeks — substantially more than the 3–5% typically seen with approved monoamine-based agents.
Mechanism of Action
Tesofensine blocks the reuptake transporters for serotonin (SERT), noradrenaline (NET), and dopamine (DAT), increasing synaptic concentrations of all three monoamines. The combined elevation of these neurotransmitters produces satiety signaling, reduced appetite, increased motivation to move, and enhanced thermogenesis. The dopaminergic component engages reward circuits in ways that reduce hedonic eating (eating for pleasure rather than hunger), which is a dimension of obesity not addressed by GLP-1 agonists. The noradrenergic component increases sympathetic tone, raising metabolic rate and fat oxidation. The serotonergic component modulates food intake through hypothalamic circuits. This triple action produces more comprehensive appetite and metabolic effects than single-target agents.
Key Research
Phase 2b obesity trial (NeuroSearch, Astrup et al., Lancet 2008, N=203): tesofensine 0.5 mg/day produced 9.2% weight loss and 1.0 mg/day produced 10.6% over 24 weeks vs 2.0% placebo — significantly outperforming any approved oral weight loss agent at the time. Heart rate and blood pressure increases were dose-dependent concerns. Combination trials with metformin or low-dose naltrexone are being explored to reduce cardiovascular burden while preserving efficacy. Not currently approved by FDA or EMA — development discontinued for primary obesity indication due to cardiovascular signal concerns. Research community use continues for weight management protocols.
~220 hours (very long half-life — steady state takes 2+ week
Tesofensine is started at a low dose (0.25–0.5 mg once daily) and may be titrated to 1 mg in research protocols. Due to its very long half-life (~220 hours), steady state takes approximately 2 weeks to achieve — dose adjustments should allow 2+ weeks between changes. Blood pressure and heart rate must be monitored throughout — baseline CV assessment is essential. Cycles of 12–24 weeks with structured off-periods are the research norm. Should not be combined with other serotonergic or adrenergic agents.
Weight Loss Protocol: Tesofensine 0.5 mg orally once daily for 24 weeks with weekly blood pressure and heart rate monitoring. Combine with GLP-1 agonist or GIP/GLP-1 dual agonist for complementary mechanisms (reduced food intake via different CNS pathways). Advanced Combination: low-dose tesofensine 0.25 mg + low-dose naltrexone for reduced cardiovascular burden while maintaining dopaminergic weight loss effects.
Reported Side Effects
Side effects summarized from animal studies and researcher community observations. Educational purposes only — not medical advice.
Cardiovascular effects are the primary concern: dose-dependent heart rate increase (average +6–8 bpm at 0.5 mg) and modest blood pressure elevation. These are manageable with monitoring but require caution in individuals with hypertension, arrhythmia, or established cardiovascular disease. Dry mouth, nausea, constipation, and insomnia are commonly reported — typical of monoamine reuptake inhibitors. Mild anxiety or jitteriness occurs in some subjects, particularly at higher doses. Serotonin syndrome risk exists if combined with other serotonergic drugs. The very long half-life means side effects are slow to resolve after dose reduction. Not suitable for use with MAO inhibitors.
Storage & Handling
Oral tablets or capsules — store at room temperature (15–25°C), away from moisture and light. Standard pharmaceutical shelf life (2–3 years). Not typically available in lyophilized research peptide format — supplied as pre-compounded oral capsules. Keep away from children and unauthorized users.
Age Verification Required
This site contains information about research peptides intended for adults 21 and older. By continuing you confirm you are of legal age in your jurisdiction.
By confirming below, you agree that you are at least 21 years of age and legally able to access this content in your jurisdiction.
Access Restricted
We're sorry, but you must be at least 21 years of age to access this site. This content contains research information intended for adults only.
Research Disclaimer
RESEARCH USE ONLY: All information, tools, and resources on Peptide Oracle are for educational and research purposes only.
Not Medical Advice: Nothing on this website constitutes medical advice, diagnosis, or treatment. This site does not replace professional medical consultation.
Not for Human Consumption: Peptides discussed are for laboratory and research purposes only. They are not approved for human use, consumption, or self-administration.
No Therapeutic Claims: We make no claims regarding the safety, efficacy, or therapeutic benefits of any peptides or compounds discussed.
Legal Compliance: You are responsible for compliance with all applicable local, state, and federal laws regarding peptide research and acquisition.
Limitation of Liability: Peptide Oracle assumes no liability for any damages resulting from use of information provided on this site.
Saved for 30 days. Reset by clearing browser data.
We use cookies to improve your experience and analyse site usage. By clicking Accept All you consent to our use of cookies. Cookie Policy
